Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul B Bennett

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Nature Biotechnology|April 8, 2006
Ion-channel drug screening galvanizedPaul B Bennett
Circulation Research|September 23, 2003
Antiarrhythmic drug target choices and screeningMichael C Sanguinetti, Paul B Bennett
Trends in Biotechnology|November 20, 2003
Trends in ion channel drug discovery: advances in screening technologiesPaul B Bennett, Heather R E Guthrie
The Journal of General Physiology|May 29, 2003
Saxitoxin is a gating modifier of HERG K+ channelsJixin Wang, Joseph J Salata, Paul B Bennett
Assay and Drug Development Technologies|April 20, 2004
High throughput ion-channel pharmacology: planar-array-based voltage clampLaszlo Kiss, Paul B Bennett, Victor N Uebele, et al.
American Journal of Physiology. Heart and Circulatory Physiology|October 22, 2002
Functional and pharmacological properties of canine ERG potassium channelsJixin Wang, Kimberly Della Penna, Hao Wang, et al.
Neurochemistry International|March 17, 2005
In vitro characterization of novel NR2B selective NMDA receptor antagonistsLaszlo Kiss, Gong Cheng, Bohumil Bednar, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Nature Biotechnology|April 8, 2006
Ion-channel drug screening galvanizedPaul B Bennett
Circulation Research|September 23, 2003
Antiarrhythmic drug target choices and screeningMichael C Sanguinetti, Paul B Bennett
Trends in Biotechnology|November 20, 2003
Trends in ion channel drug discovery: advances in screening technologiesPaul B Bennett, Heather R E Guthrie
The Journal of General Physiology|May 29, 2003
Saxitoxin is a gating modifier of HERG K+ channelsJixin Wang, Joseph J Salata, Paul B Bennett
Assay and Drug Development Technologies|April 20, 2004
High throughput ion-channel pharmacology: planar-array-based voltage clampLaszlo Kiss, Paul B Bennett, Victor N Uebele, et al.
American Journal of Physiology. Heart and Circulatory Physiology|October 22, 2002
Functional and pharmacological properties of canine ERG potassium channelsJixin Wang, Kimberly Della Penna, Hao Wang, et al.
Neurochemistry International|March 17, 2005
In vitro characterization of novel NR2B selective NMDA receptor antagonistsLaszlo Kiss, Gong Cheng, Bohumil Bednar, et al.
Pageof 1